Opton Lumo launch video clip.
5 Likes
If on Midsummer Eve at midnight you look into a well and see a fundus camera at the bottom of the well, then Optomed’s share price will be over 15 at the end of the year. 
.
(An old East Finnish saying from the 1930s). Feel free to flag if it doesn’t fit the theme.
15 Likes
https://siloton.com/2025/06/09/first-patients-trial-groundbreaking-sight-loss-prevention-technology/
I’ve mentioned this before, but let’s post it again.
In England, they have developed a coin-sized chip that enables small handheld cameras with OCT technology.
Could Optomed lease this and bring an Optomed OCT handheld camera to market? Or even buy the whole Siloton company?
Or would Opto have its own similar development project underway…it might be. But inevitably, an OCT handheld camera will come to market someday.
7 Likes
Midsummer reading for forum members, a new interview with Toku Eyes’ CEO.
18 Likes
Now things are starting to happen. When you combine this with this year’s old press release about the collaboration between these companies, we might be on the verge of something big with Lumo. That Toku desktop camera FDA approval could come any time, and then one 510(k) clearance will follow immediately.
6 Likes
Here is the clair study that is done with desktop cameras. The material should be ready this month, and the final material to be submitted to the FDA by October, according to estimates. However, quite a lot of time has been reserved for drafting that report, almost 4 months, so that will probably shorten.
7 Likes
A lot of activity for Optomed @usa. This time together with AEYE Health;
https://www.linkedin.com/posts/aeyehealth_𝗔𝗗𝗔-𝟮𝟬𝟮𝟱-𝗧𝗵𝗮𝘇𝘀-𝗮-𝗪𝗿𝗮𝗽-activity-7343274953758105601-R-mT?utm_source=share\u0026utm_medium=member_ios\u0026rcm=ACoAABJBlKwBF_39yHqkRlZMrfG6qULSPgzH-oM
21 Likes
Someone is buying like crazy… While waiting for news, I wonder if the valuation will finally start to show.
14 Likes
This has such a scalable business model, a large emerging new market (the CEO used Chan Kim’s blue ocean term) and strong winner-takes-all (or not all but a lot) dynamics that if it succeeds, it will climb very high.
Perhaps betting on this has begun?
18 Likes
Good evening!
Isn’t it true that the CE approval for the Lumo camera is not just a European approval, but it enables sales worldwide? Only the USA, China, and Japan do not accept CE approval. Only registration in the respective country is needed, and sales can begin.
The same applies to AI software, for example, Toku, which has CE approval. So, Optomed can start selling, for instance, the Lumo+Toku AI combination practically worldwide, and recurring revenue will start flowing in, even from Turkey or Nigeria.
This is how this permit issue works at least with Bioretec, so why not with Optomed and even with the aforementioned Toku.
7 Likes
It’s great that doctors’ well-being also improves with AI solutions.
15 Likes
Good Saturday evening!
How many of these AI software programs have currently received CE approval? This is, of course, thinking about the partners available for the Lumo camera. Does anyone here have comprehensive information on this? That would indeed be interesting information.
Toku Clair and Revenio/Thirona RetCad come to mind regarding these. Is Aeye Health applying for CE approval for retinopathy screening? I don’t recall reading any news about that.
Q3 and Lumo are starting soon… it would be interesting if Toku were immediately involved.
2 Likes
CE-marked AI software compatible with Lumo:
Toku Eyes – CLAiR
– CE and UKCA marking granted (2023–2024)
– Assesses cardiovascular risk from a retinal image
– Partnership agreement with Optomed confirmed in May 2024
AEYE Health – DR AI (Diabetic Retinopathy)
– CE marking granted 2023, also FDA
– Already in use with Aurora AEYE camera
– Likely compatible with the Lumo platform as well
RetInSight – AMD/iAMD analysis
– CE marking exists
– Optomed has collaborated with RetInSight
– No official announcement yet regarding integration with Lumo
Thirona RetCAD (Revenio collaboration)
– CE approval granted
– No public information on use in Optomed devices, related to Icare’s Revenio line
Potentially coming later:
Toku MyKidneyAI – CE not yet, but FDA Breakthrough Device status
Other blood pressure, Alzheimer’s, biological age, etc. – several AI developers in CE processes (e.g., RetinAI, EyRIS)
From Optomed’s perspective, the strongest evidence is for Toku CLAiR, which is certainly CE-approved and likely integrated into the Lumo camera for the European market (and possibly other markets) => Optomed’s sales team travels the world with Lumo, and some AI algorithm must surely be in the camera, otherwise, it’s impossible to demo.
AEYE Health’s DR algorithm is CE-approved, and since Lumo shares a technical platform with Aurora, it is also a very likely partner.
Q3 launch with Lumo + CLAiR immediately included = in my opinion, a very probable scenario.
25 Likes
Thanks for the answer.
It’s interesting how I had forgotten about that Aeye CE approval. Well, this forum has largely focused on that USA thing.
But great news. One could indeed assume that both Toku and AEYE are immediately involved in the Lumo launch. It’s a shame these aren’t suitable for China, but surely by the end of the year, there will be news about China’s opening with Chinese AI gadgets along with Lumo. 
5 Likes
My own focus has also been quite strongly on the events of 2025 concerning Optomed’s business and its development. I asked AI a bit about how it sees the business development and stock price reaction, and I received the following view:
Optomed – 2026 could be the company’s breakthrough year
The stock price has already risen to the 4.3 € level at the end of June, and a bigger change is brewing in the background, which could truly materialize during 2026.
The company has been building its foundation throughout 2025:
• Lumo camera received CE approval, deliveries starting in Europe
• Aurora AEYE AI software launched in the USA for diabetic eye screening
• FDA application for the US market possibly in autumn 2025
• Potential strategic AI partnerships (Toku, Thirona, CLAiR, etc.)
If these materialize, 2026 could be the first full scaling year, during which the company transitions from device sales to AI and service-based business.
⸻
What could 2026 look like? Here’s a monthly forecast:
• January–March: Lumo sales in Europe accelerate, AI revenues begin to show in financial statements
• April: Possible FDA approval for Lumo → sales begin in the USA
• May–June: ADA conferences, new oculomics pilots, AI ecosystem expands
• August–November: Q2 and Q3 results → possibility of a revenue jump if USA & EU perform well
• December: interest from international institutional investors could truly awaken
⸻
Price target analysis for the end of 2026:
• 
Bull scenario (AI breaks through, FDA ready, partners on board) → stock price 25–35 €
• 
Base scenario (Lumo & AI operational, but moderate growth) → 10–15 €
• 
Bear scenario (delays or no traction) → 3–6 €
⸻
All of this is not yet priced in – now is when things are just starting to wake up. If Optomed succeeds in becoming an AI-based medtech service company, the stock multipliers could increase many times over. And if not, the downside at current prices is still limited.
What do others think – is 2026 the “breakout year” when the company finally fulfills its AI potential?
15 Likes
Yes, it is true that 2025 will show if this is going anywhere. If 2025 shows strong growth for Aurora Aeye, and specifically in a snowball-like manner, then 2026 will almost certainly see equally strong growth, and growth will continue with Lumo in 2026 or 2027 and beyond. Most of all, I’m looking forward to those research papers from Lumo; could the cameras have been in research use before launch? If there’s excellent image quality and 99% imageability, then Optomed has handheld camera leadership and a handheld camera that is also sold as a desktop camera. According to the CEO, algorithms are coming because everyone reportedly wanted them on the platform already last year. Some algorithms in the EU sector in mid-to-late 2026 and perhaps in the US in 2027. By early 2026, we will almost certainly be on the African continent, as this business is not as regulated there. Apparently, they have been very satisfied with Aurora and the algorithm used there, so it’s hard to say how much revenue can be expected from there, but it might surprise.
Not to mention China’s binary business. Let’s hope things start rolling there too.
18 Likes
The Optomed Lumon launch video already has 20k views on YouTube. Previous videos have a few hundred to a couple of thousand views.
38 Likes
https://chinameddevice.com/innovation-diabetic-retinopathy/
In China, at least two AI algorithms received approval for retinopathy screening as early as 2020.
How exactly does this work in China now? Would it still be possible, for example, for Aeye Health’s retinopathy AI to get approval in China with Lumo? Or is there a strict ban on foreign AI software in healthcare, or a strong recommendation to use only Chinese ones?
The impression has been that Chinese software must be adopted there, for example, as a partner for Lumo. But how is this now?
Is @Juha_Kinnunen aware of this? Have you discussed this with Optomed?
10 Likes
Hi,
Yes, there has been discussion about this, I recall it being mentioned in videos sometimes. Unfortunately, China is practically a closed market for AI algorithms, meaning Western companies have no access there. For devices, there is a strong recommendation for domestic alternatives, or perhaps more of a command to use them. This is at least in the public sector; the private sector has more freedom. But if a domestic alternative is not available, then Western products can be purchased – for example, Optomed’s or Revenio’s products.
I believe it’s entirely possible to buy an Aurora camera and add local AI to it. Or even Lumo, if it were available. But Optomed would be a “camera supplier” and would not receive revenue from the AI. Regarding that data, China is apparently controlling, but pragmatic in the big picture.
And China certainly has a lot of AI expertise. My understanding is that they are in many respects at the forefront and are also willing to screen for other diseases besides diabetic retinopathy. So the pie could be very large in the future, but it will primarily be shared by local companies. And China is not exactly known for respecting patents, which is a risk when considering the country’s long-term potential. That is, if someone succeeds in copying the device (reverse engineering etc.), a local competitor might appear, after which the situation would be grim. This device would not have access to Western countries that respect patents, but the situation could be different in the Chinese market.
So, there is potential, but it’s not an unproblematic country.
30 Likes
Isn’t this Optomed joint venture in China pretty much something that can be classified as a local company? Opto’s share is 20% and the rest is owned by Chinese. The Chinese are also leading the ongoing regulatory process.
Two owners of the Chinese fund of this Optomed joint venture are among China’s largest private equity investors, listed in Fortune 500. They are unlikely to let a copied device eat into their own business, which is certainly intended to be scaled across the entire Chinese region. They have seen a big money business in this. They protect their own interests even against other Chinese companies. Optomed is not alone in this.
So, this Optomed China thing is pretty much a Chinese affair 
.
I must add here that it would be a great surprise, astonishment, and wonder if Optomed starts in China with an Aurora camera instead of Lumo. That regulatory process has dragged on so much that I assume the Lumo camera process is included there.
15 Likes